Erick L.
- Country
- France
- Department
- 1813 :Rhumatologie
Research Overview
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephropathy at High Risk of Progression
- Open-Label Extension Study Evaluating Long-Term Safety and Tolerability of Subcutaneous Secukinumab in Patients with Polymyalgia Rheumatica
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
Data & Insights
Has run more than one trial at 68 of 255 partner sites.
Specializations
Rheumatology Focus
This investigator specializes in treating polymyalgia rheumatica (PMR), concentrating on innovative therapeutic approaches for this inflammatory condition.
- Long-term disease management
- Treatment of relapsing conditions
- Inflammatory disorder therapy
The investigator's work encompasses comprehensive disease monitoring and therapeutic intervention strategies.
Treatment Innovation
The investigator explores advanced therapeutic options, including subcutaneous biological treatments combined with traditional approaches for rheumatic conditions.
- Combination therapy approaches
- Glucocorticoid management
- Sustained remission strategies
Their work focuses on developing effective treatment regimens for optimal patient outcomes.
Clinical Safety
The investigator maintains a strong focus on long-term safety assessment and tolerability monitoring in rheumatic disease treatments.
- Safety profile evaluation
- Adverse event monitoring
- Long-term treatment outcomes
Their expertise includes comprehensive safety assessment protocols in chronic condition management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.